Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.71 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31006945 | 1.00 | PLA2G2A (0.71) | PLA2G2ASMPD1BLMTP53TSHR | |
| SCHEMBL5090279 | 1.00 | PLA2G2A (0.71) | PLA2G2ASMPD1BLMTP53TSHR | |
| SCHEMBL15731932 | 1.00 | PLA2G2A (0.71) | PLA2G2ASMPD1BLMTP53TSHR | |
| SCHEMBL1568668 | 1.00 | PLA2G2A (0.71) | PLA2G2ASMPD1BLMTP53TSHR | |
| SCHEMBL25328188 | 1.00 | PLA2G2A (0.71) | PLA2G2ASMPD1BLMTP53TSHR | |
| SCHEMBL5086867 | 1.00 | PLA2G2A (0.71) | PLA2G2ASMPD1BLMTP53TSHR | |
| SCHEMBL25327393 | 1.00 | PLA2G2A (0.71) | PLA2G2ASMPD1BLMTP53TSHR | |
| SCHEMBL5095050 | 1.00 | PLA2G2A (0.71) | PLA2G2ASMPD1BLMTP53TSHR | |
| SCHEMBL971768 | 1.00 | PLA2G2A (0.71) | PLA2G2ASMPD1BLMTP53TSHR | |
| SCHEMBL317989 | 1.00 | PLA2G2A (0.71) | PLA2G2ASMPD1BLMTP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252677-A1 | ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252677-A1 | ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS | TLR3, TLR9, ADAR | PLA2G2A 930/4885SMPD1 815/4885BLM 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.